Lexicon Pharmaceuticals
Home
Contact Us
Site Map
About Us
About Us Home
Management Team
Board of Directors
Development Team
Locations
Contact Us
History
Pipeline
Drug Pipeline Home
Our Goal
Therapeutic Areas
Drug Development Team
Clinical Trials
Publications
Discovery
Discovery Home
Discovery Process
Technology
Genome5000
Medicinal Chemistry
Biotherapeutics
Patents
Academic Access
Technology Licensing
Alliances
Alliances Home
Current Alliances
Technology Licensing
Careers
Careers Home
Opportunities
Our Culture
Benefits
Community Involvement
The Woodlands
Princeton
Awards and Recognition
News
News Home
Media Inquiries
Investors
Investors Home
Media
Events
Stock Quote
SEC Filings
Annual Reports
Corporate Governance
Request Information
News Home
Media Inquiries
Subscribe
Press Releases
Filter
Display #
5
10
15
20
25
30
50
100
All
10/22/2006
Lexicon Genetics Announces $40 Million Financing
10/16/2006
Lexicon Genetics Initiating IND-Enabling Studies for LX2931 for Autoimmune Disease
10/11/2006
Lexicon Genetics Awarded Additional Grant for Study of Spinal Muscular Atrophy
09/25/2006
Lexicon Genetics Awarded Funding from DARPA to Identify Drug Targets with Potential for Improving Sleep-Related Performance
09/18/2006
Lexicon Genetics to Present at UBS Global Life Sciences Conference
09/06/2006
Lexicon Genetics Initiates Phase 1 Clinical Trial of LX6171 for Cognitive Disorders
08/01/2006
Lexicon Genetics Reports 2006 Second Quarter Financial Results
07/18/2006
Lexicon Genetics to Report Second Quarter 2006 Financial Results on August 1, 2006
07/11/2006
Lexicon Genetics Granted Exclusive License to Cellectis' Homologous Recombination Technology
06/29/2006
Lexicon Genetics Files Application for LX6171 Phase 1 Trial for Cognitive Disorders
«
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
»
Page 8 of 32
